State Street’s HilleVax HLVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-110,264
| Closed | -$219K | – | 4326 |
|
|
2025
Q2 | $219K | Sell |
110,264
-489,865
| -82% | -$896K | ﹤0.01% | 3807 |
|
|
2025
Q1 | $870K | Sell |
600,129
-7,740
| -1% | -$14.3K | ﹤0.01% | 3466 |
|
|
2024
Q4 | $1.26M | Buy |
607,869
+22,074
| +4% | +$41.4K | ﹤0.01% | 3437 |
|
|
2024
Q3 | $1.03M | Sell |
585,795
-9,650
| -2% | -$24.7K | ﹤0.01% | 3479 |
|
|
2024
Q2 | $8.61M | Buy |
595,445
+106,711
| +22% | +$1.47M | ﹤0.01% | 2640 |
|
|
2024
Q1 | $8.13M | Buy |
488,734
+71,488
| +17% | +$1.14M | ﹤0.01% | 2695 |
|
|
2023
Q4 | $6.7M | Buy |
417,246
+61,216
| +17% | +$813K | ﹤0.01% | 2799 |
|
|
2023
Q3 | $4.79M | Buy |
356,030
+2,282
| +0.6% | +$32.1K | ﹤0.01% | 2939 |
|
|
2023
Q2 | $6.08M | Buy |
353,748
+80,711
| +30% | +$1.25M | ﹤0.01% | 2904 |
|
|
2023
Q1 | $4.51M | Buy |
273,037
+12,666
| +5% | +$203K | ﹤0.01% | 3038 |
|
|
2022
Q4 | $4.36M | Buy |
260,371
+41,234
| +19% | +$744K | ﹤0.01% | 3090 |
|
|
2022
Q3 | $3.75M | Buy |
219,137
+54,965
| +33% | +$799K | ﹤0.01% | 3196 |
|
|
2022
Q2 | $1.79M | Buy |
+164,172
| New | +$1.95M | ﹤0.01% | 3509 |
|
State Street's HLVX Position: Q3 2025 in Review
State Street sold out of HilleVax (HLVX) in Q3 2025, closing a stake of 110,264 shares — an estimated $219K sold.
State Street first reported a position in HLVX in Q2 2022 and held it in 13 quarters. The position peaked at $8.61M in Q2 2024. 1 fund tracked by Wall St. Rank holds HLVX as of Q3 2025.
- State Street reported no remaining HilleVax position as of Q3 2025 after selling out during the quarter.
- State Street sold 110,264 HilleVax shares in Q3 2025, an estimated $219K.
- State Street first reported a position in HilleVax in Q2 2022 and held it in 13 quarters.
- State Street's HilleVax position peaked at $8.61M in Q2 2024.
- 1 fund tracked by Wall St. Rank held HilleVax as of Q3 2025.
Based on State Street's 13F filing for Q3 2025, filed 14 Nov 2025.